Michael Cecchini, MD
Research & Publications
Biography
News
Research Summary
Dr. Cecchini focuses on developing new treatments for patients living with advanced gastrointestinal cancers. His specific research includes leveraging innovating DNA damaging therapies as a strategy to enhance the immune response. He has participated as both a principal investigator or sub-investigator on more than 100 clinical trials. This includes cooperative group studies, industry studies, as well as investigator initiated clinical trials. He is also the national principal investigator for multiple studies. In addition to his clinical research, Dr. Cecchini collaborates with multiple laboratories to perform bench to bedside research to enhance treatment options for patients living with gastrointestinal cancers.
He currently receives research funding through his NIH K08 Career Development Award which is evaluating the relationship between DNA damage and the immune response for gastrointestinal cancers. He was also awarded a Young Investigator Award from the Conquer Cancer Foundation, during his fellowship.
Coauthors
Research Interests
DNA Repair; Gastrointestinal Neoplasms; Immunotherapy
Selected Publications
- Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the USKc M, Fan J, Hyslop T, Hassan S, Cecchini M, Wang S, Silber A, Leapman M, Leeds I, Wheeler S, Spees L, Gross C, Lustberg M, Greenup R, Justice A, Oeffinger K, Dinan M. Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US. JAMA Network Open 2023, 6: e2323115. PMID: 37436746, PMCID: PMC10339147, DOI: 10.1001/jamanetworkopen.2023.23115.
- Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal CancerCecchini M, Zhang J, Wei W, Sklar J, Lacy J, Zhong M, Kong Y, Zhao H, DiPalermo J, Devine L, Stein S, Kortmansky J, Johung K, Bindra R, LoRusso P, Schalper K. Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer. Cancer Research Communications 2023, 3: 1132-1139. PMID: 37387791, PMCID: PMC10305782, DOI: 10.1158/2767-9764.crc-23-0045.
- NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) Plus Intravenous Irinotecan Administered in Patients with Advanced Solid TumorsCecchini M, Walther Z, Wei W, Hafez N, Pilat M, Boerner S, Durecki D, Eder J, Schalper K, Chen A, LoRusso P. NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) Plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. Cancer Research Communications 2023, 3: 1113-1117. PMCID: PMC10292219, DOI: 10.1158/2767-9764.crc-22-0485.
- NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) Plus Intravenous Irinotecan Administered in Patients with Advanced Solid TumorsCecchini M, Walther Z, Wei W, Hafez N, Pilat M, Boerner S, Durecki D, Eder J, Schalper K, Chen A, LoRusso P. NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) Plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. Cancer Research Communications 2023, 3: 1113-1117. PMID: 37377610, PMCID: PMC10292219, DOI: 10.1158/2767-9764.crc-22-0485.
- Developing a definition of immune exclusion in cancer: results of a modified Delphi workshopClifton G, Rothenberg M, Ascierto P, Begley G, Cecchini M, Eder J, Ghiringhelli F, Italiano A, Kochetkova M, Li R, Mechta-Grigoriou F, Pai S, Provenzano P, Puré E, Ribas A, Schalper K, Fridman W. Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop. Journal For ImmunoTherapy Of Cancer 2023, 11: e006773. PMID: 37290925, PMCID: PMC10254706, DOI: 10.1136/jitc-2023-006773.
- Relations between mutant KRAS and TP53 subtypes and other co-mutations in pancreatic cancer.Abraham S, Zhang J, Walther Z, Parekh J, Lacy J, Cecchini M, Hu Y. Relations between mutant KRAS and TP53 subtypes and other co-mutations in pancreatic cancer. Journal Of Clinical Oncology 2023, 41: e16294-e16294. DOI: 10.1200/jco.2023.41.16_suppl.e16294.
- Pre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancerPeters G, Talcott W, Peters N, Dhanasopan A, Lacy J, Cecchini M, Kortmansky J, Stein S, Lattanzi S, Park H, Boffa D, Johung K, Jethwa K. Pre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer. Journal Of Gastrointestinal Oncology 2023, 14: 1181-1192. PMID: 37435226, PMCID: PMC10331751, DOI: 10.21037/jgo-22-1005.
- Initial results from a first-in-human, phase I study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 in patients with advanced solid tumors.Dumbrava E, Cecchini M, Zugazagoitia J, Lopez J, Jäger D, Oliva M, Ochsenreither S, Gambardella V, Chung K, Longo F, Abdul Razak A, Wermke M, Evans T, Cook N, Chenard-Poirier M, Pencheva R, Schaer D, Wagener T, Wagner A, Papadopoulos K. Initial results from a first-in-human, phase I study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 in patients with advanced solid tumors. Journal Of Clinical Oncology 2023, 41: 2502-2502. DOI: 10.1200/jco.2023.41.16_suppl.2502.
- A multi-cohort phase I/IIa clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 administered as a monotherapy, with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors: TransStar101.Janjigian Y, Sun W, Rocha Lima C, Shah S, Scott A, Monga D, Kundranda M, Sher A, Gold P, Berlin J, Patel M, Alese O, Hamilton E, Cecchini M, Van Tine B, George B, Mehta R, Xia Z, Germa C, Gabrail N. A multi-cohort phase I/IIa clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 administered as a monotherapy, with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors: TransStar101. Journal Of Clinical Oncology 2023, 41: tps4176-tps4176. DOI: 10.1200/jco.2023.41.16_suppl.tps4176.
- Abstract CT018: Safety and efficacy of three PARP inhibitors (PARPi) combined with the ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in patients (pts) with solid tumors harboring DNA damage response (DDR) alterationsYap T, Yadav S, Herzberg B, Carneiro B, Fontana E, Højgaard M, Pishvaian M, Plummer R, Werner T, Sahai V, Lheureux S, Lee E, Mettu N, Cote G, Schonhoft J, Rimkunas V, Silverman I, Wainszelbaum M, Peltz G, Fretland A, Fei K, Ulanet D, Kim I, Koehler M, Rosen E, Cecchini M. Abstract CT018: Safety and efficacy of three PARP inhibitors (PARPi) combined with the ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in patients (pts) with solid tumors harboring DNA damage response (DDR) alterations. Cancer Research 2023, 83: ct018-ct018. DOI: 10.1158/1538-7445.am2023-ct018.
- Abstract CT276: Preliminary analysis of pharmacokinetic (PK) and target engagement biomarkers from a first in human phase 1 study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964Papadopoulos K, Cecchini M, Lopez J, Jäger D, Chung K, Platten M, Prinz F, Ishii Y, Schaer D, Gutcher I, Leder G, Pencheva R, Wagener T, Scheerans C, Zieschang C, Wagner A, Stamatelos S, Dumbrava E. Abstract CT276: Preliminary analysis of pharmacokinetic (PK) and target engagement biomarkers from a first in human phase 1 study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964. Cancer Research 2023, 83: ct276-ct276. DOI: 10.1158/1538-7445.am2023-ct276.
- A phase Ia/b first-in-human, open-label, multicenter study of BI 905711, a bispecific TRAILR2 agonist, in patients with advanced gastrointestinal cancers.Harding J, Hofheinz R, Elez E, Kuboki Y, Rasco D, Cecchini M, Shen L, He M, Archuadze S, Chhaya N, Pant S. A phase Ia/b first-in-human, open-label, multicenter study of BI 905711, a bispecific TRAILR2 agonist, in patients with advanced gastrointestinal cancers. Journal Of Clinical Oncology 2023, 41: 115-115. DOI: 10.1200/jco.2023.41.4_suppl.115.
- Survival and clinical characteristics of patients with colorectal cancer and brain metastases.Gordon C, Cecchini M, Lacy J. Survival and clinical characteristics of patients with colorectal cancer and brain metastases. Journal Of Clinical Oncology 2023, 41: 29-29. DOI: 10.1200/jco.2023.41.4_suppl.29.
- Impact of early detection on cancer curability: A modified Delphi panel studySchwartzberg L, Broder M, Ailawadhi S, Beltran H, Blakely L, Budd G, Carr L, Cecchini M, Cobb P, Kansal A, Kim A, Monk B, Wong D, Campos C, Yermilov I. Impact of early detection on cancer curability: A modified Delphi panel study. PLOS ONE 2022, 17: e0279227. PMID: 36542647, PMCID: PMC9770338, DOI: 10.1371/journal.pone.0279227.
- Multiagent Chemotherapy Followed by Stereotactic Body Radiotherapy Versus Conventional Radiotherapy for Resected Pancreas CancerMokhtech M, Miccio JA, Johung K, Cecchini M, Stein S, Narang AK, Herman JM, Kunstman J, Haddock MG, Anker CJ, Jabbour S, Hallemeier CL, Jethwa KR. Multiagent Chemotherapy Followed by Stereotactic Body Radiotherapy Versus Conventional Radiotherapy for Resected Pancreas Cancer. American Journal Of Clinical Oncology 2022, 45: 450-457. PMID: 36318696, DOI: 10.1097/coc.0000000000000947.
- 371P A phase Ia/b, open-label, multicentre study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancersHarding J, Hofheinz R, Fernandez M, Kuboki Y, Rasco D, Cecchini M, Shen L, Archuadze S, Geng J, Haderk F, Pant S. 371P A phase Ia/b, open-label, multicentre study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers. Annals Of Oncology 2022, 33: s706. DOI: 10.1016/j.annonc.2022.07.509.
- Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancerLi C, Ferro A, Mhatre SK, Lu D, Lawrance M, Li X, Li S, Allen S, Desai J, Fakih M, Cecchini M, Pedersen KS, Kim TY, Reyes-Rivera I, Segal NH, Lenain C. Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer. Communications Medicine 2022, 2: 90. PMID: 35856081, PMCID: PMC9287310, DOI: 10.1038/s43856-022-00155-y.
- Abstract CT170: A phase 1/2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction adenocarcinoma (GEJ)Cecchini M, Chao J, Shyr Y, Cleary J, Uboha N, Cho M, Shields A, Pant S, Goff L, Spencer K, Kim E, Hsu C, Stein S, Thumar J, Kortmansky J, Kunstman J, LoRusso P, Ivy P, Lacy J. Abstract CT170: A phase 1/2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction adenocarcinoma (GEJ). Cancer Research 2022, 82: ct170-ct170. DOI: 10.1158/1538-7445.am2022-ct170.
- Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations.Cecchini M, Sokol E, Vasan N, Pavlick D, Huang R, Pelletier M, Levy M, Pusztai L, Lacy J, Eder J, Zhang J, Ross J. Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations. Journal Of Clinical Oncology 2022, 40: 3535-3535. DOI: 10.1200/jco.2022.40.16_suppl.3535.
- Making National Cancer Institute–Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational StudyKalra M, Henry E, McCann K, Karuturi MS, Bustamante Alvarez JG, Parkes A, Wesolowski R, Wei M, Mougalian SS, Durm G, Qin A, Schonewolf C, Trivedi M, Armaghani AJ, Wilson FH, Iams WT, Turk AA, Vikas P, Cecchini M, Lubner S, Pathak P, Spencer K, Koshkin VS, Labriola MK, Marshall CH, Beckermann KE, , Sharifi MN, Bejjani AC, Hotchandani V, Housri S, Housri N. Making National Cancer Institute–Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study. JMIR Cancer 2022, 8: e33859. PMID: 35588361, PMCID: PMC9164098, DOI: 10.2196/33859.
- Tu1119: CLINICOPATHOLOGIC FEATURES AND MOLECULAR LANDSCAPE OF BRAF MUTATED MICROSATELLITE STABLE COLORECTAL CARCINOMABeech C, Walther Z, Cecchini M, Gibson J. Tu1119: CLINICOPATHOLOGIC FEATURES AND MOLECULAR LANDSCAPE OF BRAF MUTATED MICROSATELLITE STABLE COLORECTAL CARCINOMA. Gastroenterology 2022, 162: s-889-s-890. DOI: 10.1016/s0016-5085(22)62107-3.
- Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potentialGiner-Calabuig M, De Leon S, Wang J, Fehlmann TD, Ukaegbu C, Gibson J, Alustiza-Fernandez M, Pico MD, Alenda C, Herraiz M, Carrillo-Palau M, Salces I, Reyes J, Ortega SP, Obrador-Hevia A, Cecchini M, Syngal S, Stoffel E, Ellis NA, Sweasy J, Jover R, Llor X, Xicola RM. Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potential. British Journal Of Cancer 2022, 126: 1595-1603. PMID: 35197584, PMCID: PMC9130322, DOI: 10.1038/s41416-022-01754-1.
- A first-in-human phase Ia/b, open-label, multicenter study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers.Harding J, Hofheinz R, Elez E, Kuboki Y, Rasco D, Cecchini M, Shen L, Dowling E, Archuadze S, de Pereira B, Pant S. A first-in-human phase Ia/b, open-label, multicenter study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers. Journal Of Clinical Oncology 2022, 40: tps222-tps222. DOI: 10.1200/jco.2022.40.4_suppl.tps222.
- A phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 in patients with locally advanced or metastatic solid tumors.Gabrail N, Tolcher A, Alese O, Cecchini M, Manish P, Park H, Berlin J, Hamilton E, Huang Y, Lu L, Wang J, Shi M, Tong M. A phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 in patients with locally advanced or metastatic solid tumors. Journal Of Clinical Oncology 2022, 40: tps375-tps375. DOI: 10.1200/jco.2022.40.4_suppl.tps375.
- Clinical significance and biomarker potential of MGMT protein measurement in colorectal cancer.Zhang J, Cecchini M, Desai S, Schalper K. Clinical significance and biomarker potential of MGMT protein measurement in colorectal cancer. Journal Of Clinical Oncology 2022, 40: 136-136. DOI: 10.1200/jco.2022.40.4_suppl.136.
- Clinical outcomes of first line FOLFIRINOX vs . gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Hospital SystemPatel T, Miccio J, Cecchini M, Srikumar T, Stein S, Kortmanksy J, Johung K, Lacy J. Clinical outcomes of first line FOLFIRINOX vs . gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Hospital System. Journal Of Gastrointestinal Oncology 2021, 0: 0-0. PMID: 35070386, PMCID: PMC8748034, DOI: 10.21037/jgo-21-202.
- Pre-Operative Chemoradiotherapy With or Without Induction Chemotherapy for Operable Locally-Advanced Esophageal Cancer.Peters GW, Wang S, Peters NV, Dhanasopan A, Lacy J, Cecchini M, Kortmansky JS, Stein S, Kunz PL, Lattanzi S, Park HSM, Boffa D, Johung KL, Jethwa KR. Pre-Operative Chemoradiotherapy With or Without Induction Chemotherapy for Operable Locally-Advanced Esophageal Cancer. International Journal Of Radiation Oncology, Biology, Physics 2021, 111: e68. PMID: 34701946, DOI: 10.1016/j.ijrobp.2021.07.422.
- Pre-Operative Chemoradiotherapy With or Without Induction Chemotherapy for Operable Locally-Advanced Esophageal CancerPeters G, Wang S, Peters N, Dhanasopan A, Lacy J, Cecchini M, Kortmansky J, Stein S, Kunz P, Lattanzi S, Park H, Boffa D, Johung K, Jethwa K. Pre-Operative Chemoradiotherapy With or Without Induction Chemotherapy for Operable Locally-Advanced Esophageal Cancer. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e68. DOI: 10.1016/j.ijrobp.2021.07.422.
- Can a simplified CT response criteria for vascular involvement in pancreatic adenocarcinoma after neoadjuvant therapy predict survival in patients who achieved subsequent R0 resection?Guo Y, Czeyda-Pommersheim F, Miccio JA, Mahalingam S, Cecchini M, Pahade J. Can a simplified CT response criteria for vascular involvement in pancreatic adenocarcinoma after neoadjuvant therapy predict survival in patients who achieved subsequent R0 resection? Abdominal Radiology 2021, 46: 5609-5617. PMID: 34557934, DOI: 10.1007/s00261-021-03284-5.
- A phase 1/2 open-label study of KY1044, an anti-ICOS antibody with dual mechanism of action, as single agent and in combination with atezolizumab, in adult patients with advanced malignancies.Patel M, Naing A, Burris H, Lin C, Curigliano G, Thistlethwaite F, Minchom A, Ascierto P, De Braud F, Cecchini M, Hanekom W, Sainson R, Wilson R, Quaratino S. A phase 1/2 open-label study of KY1044, an anti-ICOS antibody with dual mechanism of action, as single agent and in combination with atezolizumab, in adult patients with advanced malignancies. Journal Of Clinical Oncology 2021, 39: 2624-2624. DOI: 10.1200/jco.2021.39.15_suppl.2624.
- Estimates of stage-specific preclinical sojourn time across 21 cancer types.Broder M, Ailawadhi S, Beltran H, Blakely L, Budd G, Carr L, Cecchini M, Cobb P, Gibbs S, Kansal A, Kim A, Monk B, Schwartzberg L, Wong D, Yermilov I. Estimates of stage-specific preclinical sojourn time across 21 cancer types. Journal Of Clinical Oncology 2021, 39: e18584-e18584. DOI: 10.1200/jco.2021.39.15_suppl.e18584.
- Publication Bias in Gastrointestinal Oncology Trials Performed over the Past DecadePeters GW, Tao W, Wei W, Miccio JA, Jethwa KR, Cecchini M, Johung KL. Publication Bias in Gastrointestinal Oncology Trials Performed over the Past Decade. The Oncologist 2021, 26: 660-667. PMID: 33728733, PMCID: PMC8342580, DOI: 10.1002/onco.13759.
- Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment planGibson JA, Finberg KE, Nalbantoglu I, Cecchini M, Ganzak A, Walther Z, Sklar JL, Eder JP, Goldberg SB. Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan. The Lancet Oncology 2021, 22: 306-307. PMID: 33662283, DOI: 10.1016/s1470-2045(20)30683-5.
- Phase Ib/II open-label, randomized evaluation of efficacy and safety of atezolizumab plus isatuximab versus regorafenib in MORPHEUS-colorectal cancer.Desai J, Fakih M, Pedersen K, Hong Y, Segal N, Allen S, Bailey L, Lenain C, Lu D, Sayyed P, Schulze J, Cecchini M. Phase Ib/II open-label, randomized evaluation of efficacy and safety of atezolizumab plus isatuximab versus regorafenib in MORPHEUS-colorectal cancer. Journal Of Clinical Oncology 2021, 39: 82-82. DOI: 10.1200/jco.2021.39.3_suppl.82.
- Stage IV gastrointestinal stromal tumors: Epidemiology, treatment and outcomes in adult US patients.Uhlig J, Stein S, Lacy J, Cecchini M, Kim K. Stage IV gastrointestinal stromal tumors: Epidemiology, treatment and outcomes in adult US patients. Journal Of Clinical Oncology 2021, 39: 462-462. DOI: 10.1200/jco.2021.39.3_suppl.462.
- A phase 1b expansion study of TAS‐102 with oxaliplatin for refractory metastatic colorectal cancerCecchini M, Kortmansky JS, Cui C, Wei W, Thumar JR, Uboha NV, Hafez N, Lacy J, Fischbach NA, Sabbath KD, Gomez CM, Sporn JR, Stein S, Hochster HS. A phase 1b expansion study of TAS‐102 with oxaliplatin for refractory metastatic colorectal cancer. Cancer 2020, 127: 1417-1424. PMID: 33351187, PMCID: PMC8085021, DOI: 10.1002/cncr.33379.
- Association of Neoadjuvant Treatment Modality with Negative Margin and Pathologic Downstaging in Patients Undergoing Pancreatic Cancer Resection: A National Cancer Database AnalysisMiccio J, Mokhtech M, Jabbour S, Anker C, Patel T, Park H, Cecchini M, Salem R, Kuntsman J, Stein S, Kortmansky J, Lacy J, Narang A, Herman J, Haddock M, Hallemeier C, Johung K, Jethwa K. Association of Neoadjuvant Treatment Modality with Negative Margin and Pathologic Downstaging in Patients Undergoing Pancreatic Cancer Resection: A National Cancer Database Analysis. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e662. DOI: 10.1016/j.ijrobp.2020.07.1980.
- The Utility of Neoadjuvant Radiotherapy after Neoadjuvant Multiagent Chemotherapy in Patients with Localized Pancreatic CancerMiccio J, Talcott W, Patel T, Park H, Cecchini M, Salem R, Stein S, Kortmansky J, Lacy J, Johung K, Jethwa K. The Utility of Neoadjuvant Radiotherapy after Neoadjuvant Multiagent Chemotherapy in Patients with Localized Pancreatic Cancer. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e31-e32. DOI: 10.1016/j.ijrobp.2020.02.538.
- Targeted Therapies in Advanced Gastric CancerPatel TH, Cecchini M. Targeted Therapies in Advanced Gastric Cancer. Current Treatment Options In Oncology 2020, 21: 70. PMID: 32725377, DOI: 10.1007/s11864-020-00774-4.
- A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer.Cecchini M, Miccio JA, Pahade J, Lacy J, Salem RR, Johnson SB, Blakaj A, Stein S, Kortmansky JS, Johung KL. A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer. Pancreas 2020, 49: 904-911. PMID: 32658074, DOI: 10.1097/mpa.0000000000001592.
- P-320 Genetic testing for microsatellite instability and KRAS mutation in stage IV colorectal cancer: Trends and outcomes from the National Cancer DatabaseUhlig J, Stein S, Cecchini M, Kim H. P-320 Genetic testing for microsatellite instability and KRAS mutation in stage IV colorectal cancer: Trends and outcomes from the National Cancer Database. Annals Of Oncology 2020, 31: s193-s194. DOI: 10.1016/j.annonc.2020.04.402.
- The natural history of fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA).Goyal L, Lamarca A, Strickler J, Cecchini M, Ahn D, Baiev I, Boileve A, Tazdait M, Hannan L, Jia J, Marble H, Barzi A, Sahai V, Lennerz J, Kelley R, Bekaii-Saab T, Javle M, Uboha N, Harris W, Hollebecque A. The natural history of fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA). Journal Of Clinical Oncology 2020, 38: e16686-e16686. DOI: 10.1200/jco.2020.38.15_suppl.e16686.
- Timing and location of palliative care consultation in metastatic pancreatic cancer: A retrospective, single-center observational study.Patel T, Miccio J, Srikumar T, Prsic E, Adelson K, Kozhevnikov D, Patel K, Lacy J, Cecchini M. Timing and location of palliative care consultation in metastatic pancreatic cancer: A retrospective, single-center observational study. Journal Of Clinical Oncology 2020, 38: 770-770. DOI: 10.1200/jco.2020.38.4_suppl.770.
- Clinical outcomes of first-line FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Healthcare System.Patel T, Srikumar T, Miccio J, Lacy J, Stein S, Kortmansky J, Staugaard C, Gambaccini M, Axtmayer A, Cecchini M. Clinical outcomes of first-line FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Healthcare System. Journal Of Clinical Oncology 2020, 38: 769-769. DOI: 10.1200/jco.2020.38.4_suppl.769.
- Abstract C025: HexaBody-DR5/DR5 (GEN1029) shows potent preclinical antitumor activity in a variety of patient-derived xenograft (PDX) tumor modelsOverdijk M, Cecchini M, Strumane K, Brandhorst M, Lingnau A, Parren P, Ellekilde-Pedersen M, Forssmann U, Ahmadi T, Sasser A, Schuurman J, Breij E, LoRusso P. Abstract C025: HexaBody-DR5/DR5 (GEN1029) shows potent preclinical antitumor activity in a variety of patient-derived xenograft (PDX) tumor models. Molecular Cancer Therapeutics 2019, 18: c025-c025. DOI: 10.1158/1535-7163.targ-19-c025.
- Challenges with Novel Clinical Trial Designs: Master ProtocolsCecchini M, Rubin EH, Blumenthal GM, Ayalew K, Burris HA, Russell-Einhorn M, Dillon H, Lyerly HK, Reaman GH, Boerner S, LoRusso PM. Challenges with Novel Clinical Trial Designs: Master Protocols. Clinical Cancer Research 2019, 25: 2049-2057. PMID: 30696689, DOI: 10.1158/1078-0432.ccr-18-3544.
- OA23 Outcomes for Patients with Borderline and Locally Advanced Pancreatic Cancer: Induction Chemotherapy ± Radiation Followed by Surgery Compared to Induction Chemotherapy and Consolidative RadiationMiccio J, Cecchini M, Pahade J, Lacy J, Salem R, Johnson S, Blakaj A, Stein S, Kortmansky J, Johung K. OA23 Outcomes for Patients with Borderline and Locally Advanced Pancreatic Cancer: Induction Chemotherapy ± Radiation Followed by Surgery Compared to Induction Chemotherapy and Consolidative Radiation. International Journal Of Radiation Oncology • Biology • Physics 2019, 103: e10-e11. DOI: 10.1016/s0360-3016(19)30424-9.
- A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC).Cecchini M, Kortmansky J, Lacy J, Fischbach N, Thumar J, Sabbath K, Gomez C, Sporn J, Stein S, Hochster H. A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC). Journal Of Clinical Oncology 2019, 37: 630-630. DOI: 10.1200/jco.2019.37.4_suppl.630.
- Outcomes for patients with borderline resectable (BR) and locally advanced (LA) pancreatic cancer (PC) treated with induction FOLFIRINOX (FFX) +/- radiation (RT) followed by surgery compared to induction FFX followed by consolidative RT.Cecchini M, Miccio J, Pahade J, Lacy J, Salem R, Johnson S, Stein S, Kortmansky J, Johung K. Outcomes for patients with borderline resectable (BR) and locally advanced (LA) pancreatic cancer (PC) treated with induction FOLFIRINOX (FFX) +/- radiation (RT) followed by surgery compared to induction FFX followed by consolidative RT. Journal Of Clinical Oncology 2019, 37: 437-437. DOI: 10.1200/jco.2019.37.4_suppl.437.
- NCI 10066: A phase 1 / 2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma.Cecchini M, LoRusso P, Shyr Y, Ivy S, Sklar J, Dooley K, Lacy J. NCI 10066: A phase 1 / 2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal Of Clinical Oncology 2018, 36: tps4137-tps4137. DOI: 10.1200/jco.2018.36.15_suppl.tps4137.
- Introduction to the Yale Precision Medicine Tumor BoardCecchini M, Walther Z, Sklar JL, Bindra RS, Petrylak DP, Eder JP, Goldberg SB. Introduction to the Yale Precision Medicine Tumor Board. The Lancet Oncology 2018, 19: 19-20. PMID: 29304351, DOI: 10.1016/s1470-2045(17)30919-1.
- Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomesCecchini M, Walther Z, Sklar JL, Bindra RS, Petrylak DP, Eder JP, Goldberg SB. Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes. The Lancet Oncology 2018, 19: 23-24. PMID: 29304353, DOI: 10.1016/s1470-2045(17)30916-6.
- EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance.Cecchini M, Sklar J, Lacy J. EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance. Journal Of The National Comprehensive Cancer Network 2017, 15: 1085-1089. PMID: 28874593, DOI: 10.6004/jnccn.2017.0151.
- Response to nivolumab in radiation induced, BRCA-2 N372H variant, programed death ligand-1 negative, pleomorphic undifferentiated sarcoma.Foster Y, Cecchini M, Slater D, Neumeister V, Walther Z, Husain Z, Judson B, Deshpande H. Response to nivolumab in radiation induced, BRCA-2 N372H variant, programed death ligand-1 negative, pleomorphic undifferentiated sarcoma. Journal Of Clinical Oncology 2017, 35: 61-61. DOI: 10.1200/jco.2017.35.7_suppl.61.
- Interim analysis of perioperative modified FOLFIRINOX (mFOLFIRINOX) in resectable pancreatic cancer (PC).Cecchini M, Salem R, Zaheer Kidwai W, Kortmansky J, Fischbach N, Patel A, Hochster H, Lacy J. Interim analysis of perioperative modified FOLFIRINOX (mFOLFIRINOX) in resectable pancreatic cancer (PC). Journal Of Clinical Oncology 2017, 35: 393-393. DOI: 10.1200/jco.2017.35.4_suppl.393.
- Olaratumab for the treatment of soft tissue sarcoma.Deshpande HA, Cecchini M, Ni Choileain S, Jones R. Olaratumab for the treatment of soft tissue sarcoma. Drugs Of Today 2017, 53: 247-255. PMID: 28492292, DOI: 10.1358/dot.2017.53.4.2560077.
- Electronic Intervention to Improve Structured Cancer Stage Data CaptureCecchini M, Framski K, Lazette P, Vega T, Strait M, Adelson K. Electronic Intervention to Improve Structured Cancer Stage Data Capture. JCO Oncology Practice 2016, 12: e949-e956. PMID: 27650837, DOI: 10.1200/jop.2016.013540.
- Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort studyKasi PM, Kotani D, Cecchini M, Shitara K, Ohtsu A, Ramanathan RK, Hochster HS, Grothey A, Yoshino T. Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study. BMC Cancer 2016, 16: 467. PMID: 27412464, PMCID: PMC4944251, DOI: 10.1186/s12885-016-2491-y.
- PD-010 Association between chemotherapy-induced neutropenia at 1-month and overall survival in patients receiving TAS-102 for metastatic colorectal cancerKotani D, Pashtoon K, Cecchini M, Shitara K, Ohtsu A, Ramanathan R, Hochster H, Grothey A, Yoshino T. PD-010 Association between chemotherapy-induced neutropenia at 1-month and overall survival in patients receiving TAS-102 for metastatic colorectal cancer. Annals Of Oncology 2016, 27: ii105. PMCID: PMC4984158, DOI: 10.1093/annonc/mdw200.10.
- A retrospective analysis to assess the validity of multidisciplinary tumor boards using a new tool: The Subspecialty Academic Multidisciplinary Tumor Board score (SAMTB).Deshpande H, Hurwitz M, Cecchini M, Ciarleglio M, Deng Y, Li F, Sherwood M, Petrylak D. A retrospective analysis to assess the validity of multidisciplinary tumor boards using a new tool: The Subspecialty Academic Multidisciplinary Tumor Board score (SAMTB). Journal Of Clinical Oncology 2016, 34: e18188-e18188. DOI: 10.1200/jco.2016.34.15_suppl.e18188.
- Association of chemotherapy induced neutropenia at 1-month mark (CIN-1-month) and overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: A Cohort study.Kasi P, Kotani D, Cecchini M, Shitara K, Ohtsu A, Ramanathan R, Hochster H, Grothey A, Yoshino T. Association of chemotherapy induced neutropenia at 1-month mark (CIN-1-month) and overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: A Cohort study. Journal Of Clinical Oncology 2016, 34: e15124-e15124. DOI: 10.1200/jco.2016.34.15_suppl.e15124.
- The implementation of electronic hematology consults at a VA hospital.Cecchini M, Rose MG, Wong EY, Neparidze N. The implementation of electronic hematology consults at a VA hospital. Blood 2016, 127: 1610-1. PMID: 26809506, PMCID: PMC4807425, DOI: 10.1182/blood-2015-09-672113.
- Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplantCecchini M, Sznol M, Seropian S. Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant. Journal For ImmunoTherapy Of Cancer 2015, 3: 10. PMID: 25806109, PMCID: PMC4372324, DOI: 10.1186/s40425-015-0054-4.